Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30

$1.32−0.07 (-5.06%)

Close on Nov 13, 2026Market cap $1.34MP/E –Yield –

Transcode Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Transcode Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?